Ocular Therapeutix (OCUL) Research & Development (2013 - 2026)

Ocular Therapeutix's Research & Development history runs 14 years deep, the most recent figure standing at $66.2 million for Q1 2026.

• On a quarterly basis, Research & Development rose 368.0% year-over-year to $66.2 million in Q1 2026; TTM through Mar 2026 was $286.5 million, a 61.92% increase from a year earlier, with the FY2025 full-year figure at $197.1 million, up 54.42% from the prior year.
• Research & Development fell to $66.2 million in Q1 2026 per OCUL's latest filing, from $156.1 million in the prior quarter.
• Across five years, Research & Development topped out at $156.1 million in Q4 2025 and bottomed at $3000.0 in Q4 2022.
• The 5-year median for Research & Development is $14.7 million (2023), against an average of $32.9 million.
• Across the five-year window, Research & Development sank 99.97% in 2022 and soared 308066.67% in 2023, its largest moves.
• Year by year, Research & Development stood at $3000.0 in 2022, then surged by 308066.67% to $9.2 million in 2023, then surged by 947.97% to $96.9 million in 2024, then soared by 61.15% to $156.1 million in 2025, then sank by 57.59% to $66.2 million in 2026.
• Per Business Quant, the three latest OCUL Research & Development figures stand at $66.2 million (Q1 2026), $156.1 million (Q4 2025), and $13.1 million (Q3 2025).